about
Camurati-Engelmann disease: review of the clinical, radiological, and molecular data of 24 families and implications for diagnosis and treatmentStructural basis for bisphosphonate-mediated inhibition of isoprenoid biosynthesisImiglucerase and its use for the treatment of Gaucher's diseasePrior treatment with vitamin K(2) significantly improves the efficacy of risedronateVascular effects of bisphosphonates-a systematic review.Osteonecrosis of jaws related to intravenous bisphosphonates: the experience of a Jordanian teaching hospitalEffect of Fermented Red Ginseng Extract Enriched in Ginsenoside Rg3 on the Differentiation and Mineralization of Preosteoblastic MC3T3-E1 Cells.Hormone replacement therapy in women with spinal cord injury - a survey with literature review.Bone metabolism and clinical study of 44 patients with bisphosphonate-related osteonecrosis of the jaws.Dihydroartemisinin prevents breast cancer-induced osteolysis via inhibiting both breast caner cells and osteoclasts.Improvement of bone disease by imiglucerase (Cerezyme) therapy in patients with skeletal manifestations of type 1 Gaucher disease: results of a 48-month longitudinal cohort study.Drug-induced uveitisPrevention of bisphosphonates-induced osteonecrosis.Estimating the cost effectiveness of alternative drug treatments for postmenopausal osteoporosis.Andrographolide prevents human breast cancer-induced osteoclastic bone loss via attenuated RANKL signaling.Amorphigenin inhibits Osteoclast differentiation by suppressing c-Fos and nuclear factor of activated T cells.Effect of 17beta-estradiol and alendronate on the removal torque of osseointegrated titanium implants in ovariectomized rats.Clinical characteristics and recurrence-related factors of medication-related osteonecrosis of the jaw
P2860
Q24655306-D8DD3F2A-3CEC-4BCB-9F65-BB7A711E4C85Q27642782-27D61B8F-07AA-496B-9E59-D58357C6F339Q28287175-0159B529-271D-477E-B756-0FE84FB60C49Q33417337-A86BB8FA-1936-4DE7-AD1C-DCF3FEE5E341Q34468751-732E8082-D2B1-4B80-89CD-63ED590B9719Q35240281-D27368C4-BE31-4D3F-90BE-8478DB38D263Q35540865-A4B49138-BA1B-4264-83D4-B8A0277AEE2CQ35966781-9999CCA7-3EED-48DF-992A-6247990D0C4EQ36421443-9DB737BD-6F35-4045-87BB-86ABE1836EBEQ36442668-787C1BC0-80E6-4749-9465-03F24B95120AQ36737076-149A8F22-57AE-417E-84EA-F74755EA04D2Q36797491-56E5CA3D-1D3A-4148-987F-179CB63F8931Q37430252-13AE0AB6-071C-408B-A4C4-C206298B0DC3Q37609360-2CDC9D55-747C-4781-9924-4A7227C2424DQ39028702-9BC6A065-1113-43AB-8FBA-773561397B95Q41970844-168529C4-8353-4DE1-B43C-532019BD26A4Q50962720-C3FCCDEC-070D-45D7-A62E-6D3B0DC3ACE7Q58595822-55324E5F-E84C-40FD-A6FE-5CA4BE6D82DB
P2860
description
2003 nî lūn-bûn
@nan
2003 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Bisphosphonate treatment of osteoporosis.
@ast
Bisphosphonate treatment of osteoporosis.
@en
type
label
Bisphosphonate treatment of osteoporosis.
@ast
Bisphosphonate treatment of osteoporosis.
@en
prefLabel
Bisphosphonate treatment of osteoporosis.
@ast
Bisphosphonate treatment of osteoporosis.
@en
P1476
Bisphosphonate treatment of osteoporosis.
@en
P2093
Nelson B Watts
P304
P356
10.1016/S0749-0690(02)00069-1
P577
2003-05-01T00:00:00Z